OncoHost is a leader in next-generation precision oncology for improved personalized cancer therapy.
OncoHost combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy.
OncoHost was founded in 2017 by Dror Yeger and Yuval Shaked. The company is headquartered in Binyamina, Binyamina, Israel.
OncoHost's launched PROphet®, a personalized, real-time, dynamic 'disease navigator' which analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient (i.e., the host) in response to a given cancer therapy.
The OncoHost's PROphet® leverages advanced proteomic analysis and AI-based host response science, to provide early identification of an individual's responsiveness to cancer therapy, analysis of treatment resistance mechanisms, and potential available strategies to overcome this resistance.
OncoHost's proteomic profile is highly predictive of individual patient outcome, thus enabling personalized treatment planning. PROphet® also identifies potential drug targets, advancing the development of novel therapeutic strategies as well as rationally based combination therapies.
OncoHost is backed by OurCrowd, ALIVE Israel HealthTech VC, Leumi Partners, Menora Mivtachim, and others. The company completed a $35M Series C round on May 10, 2022. This brings OncoHost's total funding to $51M to date.